

ASTRAZENECA PLC  
Form 6-K  
November 01, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of November 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

1 November 2017 07:00 GMT

#### ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FOR RESIDUAL RIGHTS TO ANAESTHETIC MEDICINES

AstraZeneca today announced that it has completed the commercialisation agreement (announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

AstraZeneca initially entered an agreement with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US. Under the terms of the new agreement, AGI has now acquired the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines.

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

#### Media Relations

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding     | UK/Global | +44 203 749 5821 |
| Matt Kent        | UK/Global | +44 203 749 5906 |
| Gonzalo Viña     | UK/Global | +44 203 749 5916 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

#### Investor Relations

|                     |                            |                  |
|---------------------|----------------------------|------------------|
| Thomas Kudsk Larsen |                            | +44 203 749 5712 |
| Craig Marks         | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler       | Oncology                   | +44 203 749 5797 |
| Mitchell Chan       | Oncology                   | +1 240 477 3771  |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                  |  |                  |
|------------------|--|------------------|
| Christer Gruvris | Diabetes; Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| Nick Stone       | Respiratory; Brilinta                            | +44 203 749 5716 |
| US toll free     |  | +1 866 381 7277  |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC  
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 1 November 2017  
By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary